Summary. Glutathione S-transferases (GSTs) are implicated in cytotoxic drug resistance in leukaemia. In a previous study, expression of mu class GST (GSTM) was associated with poor prognosis in childhood acute lymphoblastic leukaemia (ALL), however, that study did not differentiate between individual GSTM isoforms. This study, therefore, investigated individual GSTM isoform expression in ALL blasts at the mRNA level. Leukaemic blasts from 21 children with ALL were studied. Interindividual variation in the pattern of GSTM mRNA isoform expression was demonstrated. GSTM2 transcript was expressed in all patients in contradistinction to GSTM5, which was not detected in any sample. GSTM3 and GSTM4 expression varied between individuals, with GSTM3 expressed in 62% and GSTM4 in 24% of patients. Lymphoblast expression of GSTM3 was positively related to good prognosis whereas expression of GSTM4 was not related to clinical outcome in this small cohort. No relationship was demonstrated with established indicators of prognosis, including sex, age, immunophenotype and presenting white cell count. The results suggest that expression of GSTM3 may play a role in determining prognosis in childhood ALL and could provide more information for accurate stratification of treatment. Further studies are required to determine whether there is a causal relationship between GSTM3 expression and clinical outcome.
Cytosolic glutathione S-transferases (GSTs) form a multigene family of enzymes, currently divided into four classes, a (GSTA), l (GSTM), p (GSTP) and h (GSTT), on the basis of sequence homology and immunological cross-reactivity (Mannervik et al, 1992; Tsuchida & Sato, 1992) . GSTs form an important part of intracellular detoxification pathways. They catalyse the conjugation of glutathione (GSH) with electrophilic compounds, including certain groups of cytotoxic drugs and other xenobiotics. The resulting conjugate is generally less toxic, more soluble and more readily excreted from the cell via energydependent protein pumps, including the multidrug resistance protein, MRP (Jedlitschky et al, 1996) . All GSTs are highly specific with regard to GSH but their electrophile specificity varies considerably between the classes. Furthermore, within each class, the isoforms exhibit significant differences in substrate specificity, in spite of having considerable sequence homology (Commandeur et al, 1995; Gulick & Fahl, 1995) . For example, the human l class isoenzyme GSTM1 can catalyse the conjugation of GSH with trans-stilbene oxide, a capability not shared by other GST classes or even other isoforms of the l class family (Commandeur et al, 1995) .
The level of gene product expression of the different classes of GST varies between tissues. In human liver, GSTA constitutes 80% of the total GST protein expressed, of which the GSTA1-1 isoform predominates (Van Ommen et al, 1990) . In contrast, human colonic tissues express GSTP as the major class of the GST family (Singhal et al, 1992) . Differential expression of GST subclasses can also occur within an organ. For example, in the kidney, GSTA predominates in the proximal tubules, whereas GSTP and GSTM are the major isoforms in the thin loop of Henle, distal tubules and collecting ducts (Campbell et al, 1991) .
Both GSTM1 and the h class GSTs (GSTT) exhibit interindividual differences in expression as a consequence of the following genetic polymorphisms (Zhong et al, 1993) . In approximately 50% of the Caucasian population, the GSTM1 gene is deleted from both alleles on chromosome 1 (Pemble et al, 1994) . Similarly, for the GSTT gene, which is localized to chromosome 22 (Tan et al, 1995) , a GSTT1 null genotype is described in approximately 16% of Caucasians (Chen et al, 1996) . A number of studies have emphasized the importance of these genetic polymorphisms in susceptibility to carcinogenesis. For example, an increased frequency of the GSTT1 null genotype has been described in patients with myelodysplastic syndrome (Chen et al, 1996) and the homozygous deletion of the GSTM1 gene is associated with increased risk of lung carcinoma in smokers Nakajima et al, 1995) . As yet, however, no correlation with drug resistance has been reported for either polymorphism.
Previous work reported by our group demonstrated a correlation between GSTM expression and poor prognosis in childhood ALL. In this study, we observed that patients whose bone marrow expressed GSTM, as determined by immunohistochemistry, had a significantly increased risk of relapse (Hall et al, 1994) . The antibody used was a polyclonal anti-GSTM antibody raised against GSTM purified from liver extracts and, therefore, was unable to distinguish between the isoforms within the mu class of GSTs. In order to determine if prognosis was related to the GSTM1 polymorphism gene, we examined the GSTM1 genotype in the same study population but no correlation was found between GSTM1 genotype and clinical outcome (Matheson et al, 1997) . In the absence of any studies investigating the expression of the remaining four GSTM isoforms in leukaemic blasts, we chose to study the expression of the GSTM isoforms 2-5 at the mRNA level. This was performed using reversetranscription polymerase chain reaction (RT-PCR) to examine the relationship between individual GSTM isoform expression and established indicators of prognosis in childhood ALL.
MATERIALS AND METHODS
Patient samples analysed were derived from patients presenting to major medical centres in the Netherlands, Denmark or Germany. Patients were treated according to their respective national protocols for the Dutch Childhood Leukaemia Study Group (SNWLK), the Danish Nordic Society of Paediatric Haematology and Oncology (NOPHO) and the German Co-operative ALL (COALL) Study Group. The bone marrow and blood samples were sent to the Haematology, Oncology, Immunology (HOI) Laboratory, Vrije University, Amsterdam, where the initial sample preparation was performed. Leukaemic blast pellets were prepared by Ficoll extraction and pellets of 1 · 10 7 cells were stored at )80°C for subsequent RNA extraction.
Total RNA extraction was performed using caesium chloride ultracentrifugation based on the method of Chirgwin et al (1979) .
RNA preparation and reverse transcription was performed using the Superscript tm preamplification system (Gibco BRL, Paisley, UK following manufacturer's recommendations). Total RNA (0AE1 lg) was used together with 50 pmol/l of an oligo dT primer to programme each reverse transcription reaction. The resulting first strand cDNA was either maintained on ice, if PCR was to be performed immediately, or stored at )20°C.
PCR was performed in a Perkin Elmer (Bucks, UK) thermal cycler (Model 480). Each reaction mixture contained; 1 · Bioline buffer, 2AE5 units Taq (Promega, Southampton, UK), 200 lmol/l dNTPs, 1AE5 mmol/l MgCl 2 , 2 ll cDNA and 50 pmol/l of the appropriate primer. Positive controls for GSTM isoforms 2-4 and GADPH were prepared using cDNA derived from a neuroblastoma cell line, SHSY1, known to express these transcripts. No positive control for GSTM5, however, could be obtained.
Primer sequences are shown in Table I . GADPH primers were used as an internal standard as described by Moretti et al (1994) . Primers were synthesized using an automated DNA/ RNA synthesiser (model 292; Applied Biosystems, CA, USA). *PCR product size generated from a cDNA template. All primers were targeted to exonic sequences. GAPDH primers were used as an internal standard as described by Moretti et al (1994) .
The PCR profile consisted of 35 cycles of 94°C for 3 min, 56°C for 1 min and 72°C for 30 s. The products were electrophoresed through 2% agarose and visualized using ethidium bromide, alongside a 123 bp marker (Gibco). PCR products for each of the GSTM isoforms 1-5 are shown in Fig 1. If a band of the appropriate size was visible, the sample was designated as positive for mRNA expression ('1' in Table II) , while if no band was visible at the expected base-pair size, this was designated as negative ('0' in Table II ). The band was designated positive irrespective of the degree of intensity. The data were analysed without knowledge of the clinical details of the patients. RT-PCR products were separated by agarose gel electrophoresis and visualized with ethidium bromide. '1' designates the presence of the correct RT-PCR product. '0' designates no detectable RT-PCR product. GADPH was used as a positive control for the reverse transcription.
The identity of PCR products was verified by restriction fragment length polymorphisms (RFLP) using the endonucleases Dde1, SfaN1 and Mbo1 (NE Biolabs, Herts, UK). PCR products were separated by electrophoresis through 3AE5% Genetic Technology Gradeä(GTG) Nusieve agarose gels, and the PCR bands visualized and purified (Genelute TM ) prior to restriction endonuclease digestion. RFLP analyses for GSTM 2, 3, 4 and 5 all generated the predicted size products.
RESULTS
Ten male and 11 female patients were studied (Table III) . The mean age at presentation was 63 months, range 4-135 months. Three samples were T-lineage ALL immunophenotype and 18 were B-lineage immunophenotype.
Representative results are shown in Figs 2 and 3, demonstrating positive expression of mRNAs encoding GSTM2, M3, M4 and GADPH. In two patients, two separate pellets were available and were used to confirm the reproducibility of the technique (data not shown). The results for all the patients included in this study are shown in Table II . GSTM2 mRNA was expressed in all but one patient sample while that for GSTM5 was not expressed in any of the samples included in this study. GSTM3 transcripts were expressed in 13 samples (62%) and for GSTM4 in five samples (24%). In only two samples were both T  female  135  46  4093  preB  female  25  37  4483  C  male  86  49  4506  preB  male  25  71  6597  C  female  4  492  6920  C  female  43  356  7275  preB  male  49  20  7335  T  male  131  371  7346  C  female  64  26  7376  C  male  61  81  7698  C  female  68  36  7792  preB  female  36  95  7811  preB  male  42  10  7821  preB  female  52  60  7874  C  male  73  103  7965  C  female  45  5  8091  C  male  88  6  8096  T  male  126  800  8348  preB  female  28  54 *Immunophenotype: C, common ALL; N, null-type ALL; preB, early B-lineage ALL; T, T-lineage ALL.
Peripheral blood white cell count at initial presentation. GSTM3 and GSTM4 mRNA species co-expressed. The 'housekeeping' gene GADPH was used as a positive control for each cDNA sample and was shown to be present in all samples analysed.
The relationships between expression of GSTM 3 and 4 and known indicators of prognosis in childhood ALL were analysed. GSTM2 and GSTM5 were not considered in this analysis as their ubiquitous presence or absence would preclude any significant contribution to differences in clinical outcome. The expression of GSTM3 and GSTM4 was shown to be the same in male and female patients. Similarly, no significant relationships were demonstrated between expression of either GSTM3 or GSTM4 transcripts and age (MannWhitney U-test P ¼ 0AE12 and 0AE4 respectively) or white cell count (WCC) at presentation (Mann-Whitney U-test P ¼ 0AE44 and 0AE76 respectively). All of the three samples immunophenotyped as T-lineage ALL expressed GSTM3 but none expressed GSTM4 whereas, of those samples immunophenotyped as B lineage, 10/18 (56%) expressed GSTM3 and 5/18 (28%) expressed GSTM4 ( Table IV) .
The availability of cytogenetic data for the patients included in this study was limited. As historical samples were used, it was not possible to undertake any further molecular analysis. Therefore, any relationship between GSTM isoform expression and cytogenetic abnormalities could not be examined.
Survival data were available on 20 of the 21 patients studied. The overall 5-year survival for the cohort of patients in this study was 55% and the 5-year event-free survival was 35% (Fig 4) . Events included one patient whose death occurred during induction therapy, while in all other patients the events were relapses. A significantly better overall survival was observed in patients with blasts expressing GSTM3 mRNA [Fig 5 , log-rank test 5AE22, degrees of freedom (d.f.) 1, P ¼ 0AE02]. These patients also showed better event-free survival (log-rank test 6AE18, d.f. 1, P ¼ 0AE01). In contrast, clinical outcome was not influenced by expression of the GSTM4 transcript (Fig 6) .
DISCUSSION
Interindividual variation in the expression of GSTM isoforms in leukaemic blasts was demonstrated in this cohort of children with ALL. GSTM2 mRNA transcripts were expressed in 95% of patients analysed whereas no patient expressed GSTM5. The expression of GSTM3 and GSTM4 displayed the greatest interindividual variation. These two isoform transcripts were expressed simultaneously in only two patients (9AE5%). GSTM3 was expressed in all of the three T-lineage samples analysed and in 10 of 18 (56%) B-lineage samples, whereas GSTM4 was only expressed in five of 18 (28%) B-lineage samples and not in the T-lineage samples. No relationships were demonstrated between the mRNA expression of either GSTM3 or GSTM4 and other established indicators of prognosis in childhood ALL, including sex, age at presentation and presenting WCC. GSTM3 expression was positively related to clinical outcome, however, no relation was found between GSTM4 expression and survival. The Kaplan-Meier survival curves generated in this study should be interpreted with caution because the number of patients included in the study was small and the follow-up period for many patients was short. Nevertheless, the results of this initial analysis suggest that further investigation of the lymphoblast expression of GSTM isoforms with a larger number of patients could prove valuable.
The five-year overall and event-free survival of the patients included in this study (55% and 35% respectively) were considerably less than currently reported survival figures. However, there was an inherent bias in selection of patients for this study. A large number of cells was needed to obtain sufficient mRNA for analysis. Samples from patients presenting with a high WCC were, therefore, more likely to be sent for research purposes and result in a successful RNA extraction. This was reflected in the study cohort which included a high proportion of patients with a high WCC at presentation; 11 from 21 patients (52%) had a presenting WCC greater that 50 · 10 9 /l. A high WCC is a known predictor of poor prognosis and could account for the poor clinical outcome of patients included in this study.
This is the first reported study of individual GSTM isoform expression at the mRNA level in childhood leukaemia. Earlier studies of GSTM expression in leukaemia have used immunologically based techniques. We previously reported that expression of GSTM was related to an increased risk of relapse in childhood ALL (Hall et al, 1994) but could not differentiate between GSTM isoforms. The rabbit polyclonal antibodies used in that study were raised against GSTM purified from hepatic extracts, which comprise predominantly of GSTM1 (Hall et al, 1994) . Recently, Den Boer et al Kaplan-Meier overall and event-free survival curves for childhood ALL. Survival data were available on 20 of the 21 patients analysed. Vertical lines represent censored patients. Five-year overall survival was 55% and 5-year event-free survival was 35%.
Fig 5.
Comparison of overall and event-free survival in children with ALL grouped according to expression of GSTM3 in leukaemic blasts. Event-free survival data were available on 20 of the 21 patients analysed. Vertical lines represent censored patients. Both overall and event-free survival were significantly increased in patients with lymphoblasts positive for GSTM3 (log-rank test 6AE18, d.f. 1, P ¼ 0AE01 and log-rank test 5AE22, d.f. 1, P ¼ 0AE02 respectively).
(1999) examined GST expression in childhood leukaemia by flow cytometry using the same antibodies. They also found no relationship between GSTM expression and known indicators of prognosis, however, the follow-up period on their patients was too short to yield survival data. Again, the technique used by Den Boer et al (1999) could not differentiate between individual GSTM isoforms. Campbell et al (1991) reported that antisera raised against GSTM1 or GSTM2 did not cross-react with GSTM3. It is, therefore, probable that in our previous studies, the immunopositivity reflected either GSTM1 or M2 expression rather than expression of the other GSTM isoforms.
It is known that GST expression is tissue-type specific, as is the expression of each of the GSTM isoforms (Campbell et al, 1991; Ramjee et al, 1994; Rowe et al, 1997) . Furthermore, interindividual variation in GSTM1 expression, as a result of genetic polymorphism, is well known Approximately 40-60% of the population are homozygous to the GSTM1 null gene (Bell et al, 1992; Ketterer et al, 1992) . More recently, allelic variation in the GSTM3 gene has been reported but, unlike GSTM1, this is not due to a null allele but results from a 3 bp deletion in intron 6 (Inskip et al, 1995) . Studies examining the association between GSTM3 polymorphism and the risk of lung and colorectal cancer suggest the incidence of the GSTM3 allelic variant to be around 20% in the normal population (Loktionov et al, 2001; Risch et al, 2001 ). Interindividual differences in expression of GSTM4 in a given tissue type have not been previously reported. Moreover, although GSTM3 polymorphism has been studied in the context of cancer susceptibility, it has not been studied in the context of leukaemia and there no are previous studies examining the influence of GSTM3 expression on response to treatment.
The mechanism by which expression of GSTM3 might convey a survival advantage in childhood ALL is presently unclear and warrants further investigation. GSTs are usually described as detoxifying enzymes, therefore, overexpression of an isoform would not be expected, a priori, to lead to increased cytotoxicity of a drug. Cytotoxic GST conjugates have been described (Pickett & Lu, 1989; Gulick & Fahl, 1995) but the conjugates were of halogenated hydrocarbons rather than the cytotoxic drugs used in the treatment of leukaemia. There is considerable evidence that the GSTM3 protein is the most distantly related member of the GSTM family. The protein encoded by the GSTM3 gene shares only 70% homology with other GSTM isoforms, and has atypical catalytic and structural properties, differing significantly from other GSTs. The GSTM 1-5 gene cluster has been mapped to human chromosome 1p13 (Pearson et al, 1993; Gough et al, 1994) . A physical map of the five l class genes demonstrated that four of these are orientated in a head to tail array, 5¢-M4-M2-M1-M5-3¢ (Xu et al, 1998) . More recently, the GSTM3 gene was identified as having an inverted orientation, situated downstream from GSTM5 in a 5¢-M5 3¢-3¢-M3 5¢ orientation (Patskovsky et al, 1999) . A greater knowledge of the physicochemical properties of human GSTM3 and the factors regulating its expression are required before any mechanism of enhancing survival in childhood leukaemia can be postulated.
It is possible that expression of GSTM3 itself does not directly contribute to the mechanism for a good treatment response but is simply a marker of altered expression of an unrelated gene. It is interesting to note that chromosome 1 is frequently involved in recurrent gene rearrangements in ALL (Nourse et al, 1990) , however, breakpoint loci in the vicinity of the GSTM gene cluster have not yet been reported. Improvement in the outlook for children with acute leukaemia might be achieved by directing more intensive therapy to 'high-risk' disease. For patients predicted to have a good prognosis, less intensive treatment may reduce both short-and long-term morbidity without an increase in mortality. This approach assumes that patients with resistant disease can be accurately identified. WCC, immunophenotype, and cytogenetics. Furthermore, in a current Comparison of overall and event-free survival in children with ALL grouped according to expression of GSTM4 in leukaemic blasts. Survival data were available on 20 of the 21 patients analysed. Vertical lines represent censored patients. There was no significant difference between GSTM4-positive and -negative lymphoblasts for overall survival (log-rank test 0AE01, d.f. 1, P ¼ 0AE92) and event-free survival (log-rank test 0AE11, d.f. 1, P ¼ 0AE74).
Dutch-German collaboration, in vitro drug sensitivity data are being used to stratify patients. However, a recent prospective study analysing the predictive values of the traditionally accepted indicators of prognosis found the prognostic information was contained in four variables: age, sex, WCC and cytogenetic features (Donadieu et al, 1998) . The predictive power of each variable was low and it was suggested that each factor accounted for no more than 4% of the overall variability in prognosis. To date, there appears to be no single determinant of resistant disease in childhood leukaemia. Our results suggest that mRNA expression of GSTM3 was associated with good prognosis, however, further studies are indicated. This study was limited by the selection bias in the cohort towards patients with high WCC. Further studies involving a greater number of patients would be required to establish the true predictive power of GSTM3 expression in childhood ALL. If expression of GSTM3 proves to have a direct role in determining clinical outcome in childhood ALL, it may be possible to exploit this observation in the development of novel therapeutic agents. 
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